ASX:CU6 Clarity Pharmaceuticals (CU6) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Clarity Pharmaceuticals Stock (ASX:CU6) 30 days 90 days 365 days Advanced Chart Get CU6 alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket Capitalization$1.17 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewClarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.Read More… Receive CU6 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clarity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CU6 Stock News HeadlinesClarity Pharmaceuticals: Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commencesMay 20, 2025 | finanznachrichten.deRegistrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commencesMay 20, 2025 | finance.yahoo.comGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.May 28, 2025 | Weiss Ratings (Ad)Health Check: There’s no Biden time as Clarity launches prostate cancer study aimed at early detectionMay 20, 2025 | msn.comClarity Pharmaceuticals Launches Phase III Trial for Prostate Cancer DiagnosticMay 19, 2025 | tipranks.comTrump executive order to hit these 3 ASX pharmaceutical stocksMay 14, 2025 | msn.com3 ASX Penny Stocks With Market Caps Larger Than A$500MMay 13, 2025 | finance.yahoo.comSECuRE trial update: First patient treated in the Phase II Cohort ExpansionApril 17, 2025 | morningstar.comSee More Headlines Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolASX:CU6 CIKN/A Webwww.claritypharmaceuticals.com Phone61 2 9209 4037FaxN/AEmployees41Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.32 million Net Margins-481.09% Pretax MarginN/A Return on Equity-42.46% Return on Assets-24.19% Debt Debt-to-Equity RatioN/A Current Ratio19.05 Quick Ratio13.19 Sales & Book Value Annual Sales$11.51 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$0.51 per share Price / BookN/AMiscellaneous Outstanding Shares319,670,000Free FloatN/AMarket Cap$1.17 billion OptionableNot Optionable Beta1.58 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (ASX:CU6) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clarity Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Clarity Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.